ClinicalTrials.gg
CompletedNCT04578691Updated Nov 10, 2022

Study to Evaluate the Safety and Clinical Outcome of Using Navigation System in Pedicle Screw Placement in Spine Surgery

An interventional study of "Anatase" Spine Surgery Navigation System and Medtronic Stealthstation S7 Treatment Guidance System in Spinal Tumor, Traumatic Injury of Spine and Degenerative Spine Disease, sponsored by Taipei Veterans General Hospital, Taiwan. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-10.

Sponsored by Taipei Veterans General Hospital, Taiwan · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

The research project is testing whether in screw insertion of spine surgery using "Anatase" Spine Surgery Navigation System is at least as safe and accurate as using O-arm assisted spine surgery- Medtronic Stealthstation S7 Treatment Guidance System.

Read the detailed description

Pedicle screw insertion is performed to treat the patients with spine conditions, including degenerative, traumatogenic, and neoplastic lesions. Accurate insertion of pedicle screw is a crucial step which directly affects the surgical outcomes. In order to place the screws safely and accurately, various conventional techniques have been used, focusing on marking anatomical locations, entry points and insertion angles. Since the early 1990, the methods using computer systems that allow real-time image processing have been explored in order to improve the accuracy of pedicle screw placement.

The Medtronic StealthStation® S7® System is a hardware platform that enables real-time surgical navigation using radiological patient images. The application software reformats patient-specific CT or MR images acquired before surgery, or fluoroscopic images acquired during surgery, and displays them on-screen from a variety of perspectives. The "Anatase" Spine Surgery Navigation System is indicated for precisely positioning of surgical instruments and/or implants during general spinal surgery, such as pedicle screw placement.

This study will be a two-arms, single center, evaluator blind, controlled, parallel, randomised study in patients with pedicle screw placement in spine surgery. This trial will include patients need to undergo pedicle screw placement surgery with indication of spinal tumor, traumatic injury or degenerative spine disease (Pedicle screws placed from 10th thoracic vertebra to first sacrum), who are ≥20 years and ≤80 years of age with Body Mass Index (BMI) \< 40 kg/m2 and Spine T-Score ≥ -2.5.

02

Conditions studied

  • Spinal Tumor
  • Traumatic Injury of Spine
  • Degenerative Spine Disease

Keywords

  • Pedicle screw placement surgery
  • 10th thoracic vertebra to 1st sacrum
03

In context

Spinal Cord Neoplasms

105 studies on the registry are indexed under Spinal Cord Neoplasms; 27 are open to participants now.

This study's enrollment of 55 is close to the median of 50 across 69 interventional studies indexed under Spinal Cord Neoplasms.

Browse Spinal Cord Neoplasms studies →

Lead sponsor

Taipei Veterans General Hospital, Taiwan is the lead sponsor of 338 studies on the registry; 74 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who need to undergo pedicle screw placement surgery with indication of spinal tumor, traumatic injury or degenerative spine disease.
  2. Pedicle screws placed from 10th thoracic vertebra to first sacrum.
  3. Age ≥20 years and ≤80 years.
  4. (BMI) \< 40 kg/m2.
  5. Spine T-Score by Dual Energy X-ray Absorptiometry ≥ -2.5, 60 days prior to surgery.
  6. The subject is willing and able to comply with the procedure and requirements of this trial.
  7. The participant is able to understand and provide , and has signed their written informed consent in accordance with IRB requirements.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant women.
  2. Hereditary or acquired haemorrhagic diathesis or coagulation factor deficiency.
  3. Be on uncontrolled Diabetes mellitus.
  4. Any history of stroke within the previous 6 months.
  5. Any history or current evidence suggestive of Coronary Artery Disease or Cerebral Vascular Accident within the previous 6 months, including clinical, , laboratory, or imaging findings.
  6. Any terminal illness such that the patient would not be expected to survive more than 6 months.
  7. Creutzfeldt-Jakob disease.
  8. Known allergy to stainless steel (device material).
  9. Have a systematic or local infection, which may increase study risk.
  10. such as but not limited to Acquired Immunodeficiency Syndrome (AIDS), infection, Severe Combined Immunodeficiency Syndrome, Thymic Hypoplasia.
  11. Immunologically suppressed, or has received systemic , excluding nasal steroids, at any dose daily for > 1 month within last 12 months.
  12. Any condition that, in the judgment of the investigator, could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
  13. Former spinal surgery may interfere with the present trial.
  14. Participation in any study in the last 30 days or current enrolment in any trial. Non- interventional Studies are not considered exclusion.
  15. Any condition that increases anesthesia risk.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    "Anatase" Spine Surgery Navigation System

    Using "Anatase" Spine Surgery Navigation System in pedicle screw placement in spine surgery

    Device: "Anatase" Spine Surgery Navigation System

  • Active comparator
    Medtronic Stealthstation S7 Treatment Guidance System

    Using Medtronic Stealthstation S7 Treatment Guidance System in pedicle screw placement in spine surgery

    Device: Medtronic Stealthstation S7 Treatment Guidance System

Interventions

  • Device"Anatase" Spine Surgery Navigation System

    using navigation system in pedicle screw placement in spine surgery

  • DeviceMedtronic Stealthstation S7 Treatment Guidance System

    using navigation system in pedicle screw placement in spine surgery

06

What researchers measure

Primary outcomes

  1. Rate of screw outside the vertebral body

    Rate of screw outside the vertebral body as measure by post CT image which perform not later than discharge.

    Time frame: not later than discharge, up to 14 days

Secondary outcomes

  1. Difference between the actual and virtual (navigation image) of screw's sharp point position

    Blind Assessor will measure the distance (mm) between the actual (post-CT) and virtual (baseline CT) of screw's sharp point position.

    Time frame: not later than discharge, up to 14 days

  2. Difference between the actual and virtual (navigation image) angle of screws

    Blind Assessor will measure the difference of angle (°) between the actual (post-CT) and virtual (baseline CT)screws.

    Time frame: not later than discharge, up to 14 days

  3. Blood loss during surgery (mL)

    record the blood loss during surgery (mL)

    Time frame: operation 1 day

  4. Total intraoperative radiation exposure for the operator and patient

    Record the total intraoperative radiation exposure of operator and patient wearing TLD badges

    Time frame: 1 day, the TLD badges will be detected

  5. Mean time required for preparation of screw placement (min)

    Record the mean time required for preparation of screw placement (min)

    Time frame: operation 1 day

  6. Time to accomplish each screw insertion (min)

    Record the time to accomplish each screw insertion (min)

    Time frame: operation 1 day

  7. Ratio of revision surgery within 3 months after main surgery

    Record ration of revision surgery within 3 months after main surgery

    Time frame: after 3 months of surgery

  8. Length of postoperative hospital stay

    Record length of postoperative hospital stay

    Time frame: Discharge day, up to 14 days

  9. Adverse event (AE) and serious AE (SAE) incidence rates during the trial

    Record Adverse event (AE) and serious AE (SAE) during the trial

    Time frame: 90 days

07

Study locations

1 site
  • Taipei Veterans General Hospital
    Taipei, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jun 2022, 23 months.

Of 21 interventional studies with no phase under Spinal Cord Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 84. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2020
First posted
Oct 8, 2020
StartActual
Jun 29, 2020
Primary completionActual
Jun 3, 2022
CompletionActual
Aug 31, 2022
Last update
Nov 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04578691
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Jun 29, 2020
Primary completion
Jun 3, 2022
Completion
Aug 31, 2022
Last update
Nov 10, 2022

Study contacts

Tsung-Hsi Tu
principal investigator · Taipei Veterans General Hospital, Taiwan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion